The complex outpatient psychiatric medication management visit is the most frequently mis-documented encounter in the field. The visit itself is straightforward to a practicing clinician: a patient with a multi-year history, three or four active diagnoses, four to seven medications, partial response to the current regimen, a new psychosocial stressor, and a decision to make about whether to escalate, augment, switch, or hold. The note is harder. The standard SOAP structure does not naturally accommodate the chain of reasoning, and the result is often a chart where the assessment is two sentences and the HPI is six paragraphs of medication history that should have been somewhere else.

This guide covers what the note should contain, in what order, and the prose patterns that make the documentation hold up to peer review, payer audit, and the simple test of being readable by another clinician taking over the case.

What the visit actually is

A complex med-management follow-up has six clinical questions to answer:

How is the patient doing now, in patient-reported terms and in observable mental status terms?
What has changed since the last visit, in symptoms, function, life context, and treatment adherence?
What is the current state of the regimen, including doses, durations, and tolerability?
What is the response and tolerability picture across the regimen as a whole?
What is the clinical decision today, and why?
What is the plan and the reassessment timeline?

The note structure should make all six visible. A tight assessment paragraph that ties the answers together is the part the chart hinges on.

Section by section

Chief complaint

One sentence. The patient’s reason for being seen today, in language close to the patient’s own. “Follow-up on bipolar II, depressive episode, with concern about a flat plateau in mood since the last visit” is a chief complaint. ” Follow-up” is not.

Interval history (not HPI in the classic sense)

The interval history is the section where most complex med-management visits accumulate too much content. Discipline matters here.

What belongs:

Symptom trajectory since the last visit, with patient-reported severity and any objective markers (PHQ-9, GAD-7, MDQ, sleep tracking, side-effect logs).
Medication adherence, with corroborating evidence where relevant (refill history, blood levels for lithium or valproate, UDS for controlled substances).
Functional status: work, school, relationships, sleep, appetite, exercise, substance use.
New stressors or context changes.
Side effects, in patient-reported terms.
Any acute events: ED visits, hospitalizations, incidents.

What does not belong:

Full medication history. This goes in the medication list section if it is not already in the longitudinal chart.
Past psychiatric diagnoses. These belong in the past psychiatric history section of the chart.
Detailed family history, except where it has clinical relevance to today’s decision.
The differential diagnosis. That belongs in the assessment.

Length is a forcing function. A complex med-management interval history should fit in three to five clear paragraphs. If it sprawls beyond that, content is in the wrong section.

Mental status examination

The MSE on a complex med-management visit is the point where the chart establishes that the clinician was actually present and observing. Make it specific. Generic MSE paragraphs that read identically across visits are the highest-yield target for a chart-review critique.

What “specific” looks like:

Affect described in observed terms with range and reactivity (“constricted, mildly depressed, reactive within a narrow range”) rather than stock adjectives.
Thought process noted in observed terms (“linear and goal-directed today, in contrast to the loose associations noted at the prior visit”).
Speech, psychomotor activity, and any cognitive observations made during the conversation.
Suicide and homicide risk in the form actually assessed, with reference to the C-SSRS or your standard instrument.
Insight and judgment in clinical terms, not as boilerplate.

If the MSE is the same word for word as the prior visit and the rest of the note describes a change, the inconsistency itself is a chart vulnerability. Edit the MSE to match the visit.

Current regimen and tolerability

Render the current regimen as a structured list, not as prose. Each medication: drug name, dose, frequency, duration on current dose, indication, and tolerability summary.

A regimen list might read:

Lamotrigine 200 mg HS, on this dose since 2024-07, indicated for bipolar II maintenance. Tolerated well, no rash, no cognitive complaints.
Bupropion XL 300 mg AM, on this dose since 2025-11, indicated for bipolar II depression augmentation. Mild jitteriness initially, resolved.
Quetiapine 50 mg HS, on this dose since 2026-01, indicated for sleep and anxiolysis. Mild morning grogginess, manageable.
Hydroxyzine 25 mg HS PRN, used 2-3x/week, indicated for anxiety PRN. No issues.

Four lines, not four paragraphs. The structure makes the regimen scannable, which is exactly what a covering colleague or a reviewer needs.

Response and tolerability across the regimen

This is where the visit’s clinical work starts to surface. A short paragraph that ties symptoms to the current regimen.

Patient is in partial remission on the current regimen. Depressive symptoms are improved from a PHQ-9 of 19 in 2025-11 to 12 today, with most of the improvement in the first 8 weeks of bupropion augmentation. Residual symptoms are concentrated in sleep, energy, and motivation. Anxiety is improved from a GAD-7 of 16 to 9, with quetiapine providing the most subjective benefit at the cost of mild morning grogginess. Tolerability is acceptable across the regimen. No metabolic, hepatic, or cognitive concerns on the current monitoring.

This paragraph does the work that a templated assessment would skip. It connects the patient’s experience to the medications and produces a defensible picture of where the patient is now.

Assessment

The assessment is where the clinician’s thinking shows up explicitly. It should answer two questions: what is the diagnostic and clinical formulation today, and what is the decision.

A complex assessment looks roughly like this:

Bipolar II disorder, currently in a partial-response depressive episode of approximately 6 months’ duration, with anxiety as a long-standing comorbidity. The current regimen has produced meaningful but incomplete response. The depressive plateau in the past 4 weeks, in the context of stable adherence and adequate trial duration on the current doses, suggests the regimen has reached its asymptote. The clinical decision today is between augmentation with a third agent, rotation of the bupropion to another stimulating antidepressant, or addition of psychotherapy intensification rather than further pharmacologic change. Patient prefers a non-pharmacologic addition first; agreed.

That paragraph is the chart. Everything before it sets up the reasoning; everything after it implements the decision.

Plan

The plan is the implementation. Render it by domain:

Medications: continue current regimen at current doses for 4 more weeks. No changes today.
Psychotherapy: increase from biweekly to weekly with the current therapist. Discussed coordination of care.
Monitoring: PHQ-9 and GAD-7 at next visit. Repeat lithium level not indicated this cycle.
Safety: C-SSRS administered today, low acute risk, low to moderate chronic. Standard safety plan in effect. Crisis line reviewed.
Follow-up: 4 weeks. Sooner if symptoms worsen.

Specific. Time-bound. Tied to the assessment.

The decision-justification problem

Payer audits and peer reviews focus on the decision. The chart should make it easy to find the reasoning behind whatever was decided.

If the decision is to continue the current regimen, the assessment should explain why. “Adequate trial duration on the current dose, partial response, patient preference for non-pharmacologic intensification first” is reasoning. “Continue current treatment plan” is not.

If the decision is to escalate, the assessment should connect the symptoms, the trial duration, and the next step. ” Inadequate response after 12 weeks on bupropion 300 mg with full adherence; rotating to vortioxetine 10 mg daily to assess for differential response in the depressive presentation” is reasoning.

If the decision is to taper or stop a medication, the chart should show the rationale and the monitoring plan for the change.

The pattern is the same across all three: connect the data to the decision in prose, not as a bullet list, in the assessment section.

Where Nextvisit fits

For complex med-management visits, two parts of the platform do most of the work.

First, the longitudinal view. AriaMD has access to the patient’s full chart, prior notes, medication history, and scale trends. The draft of today’s interval history reflects what has actually changed since the last visit, with explicit references rather than recapitulating the entire history. The medication list section pulls from the structured medications data on the patient profile (/patient/[uuid]/medications) rather than restating it from scratch.

Second, the assessment voice. The custom-template prompt for med-management visits should explicitly instruct the system to produce clinical reasoning prose tied to the data, not a templated assessment. A few sentences in the prompt body about how the assessment should read, plus a worked example, are enough to shift the output from generic to specific. The “Build a custom intake template” guide at /guides covers the editor mechanics.

The Treatment Pulse view (/patient/[uuid]/treatment-pulse) and the AI Timeline (/patient/[uuid]/timeline) provide the cross-visit context that makes the today’s-decision justification straightforward to write. Trends, prior responses, prior side effects, and prior decisions are visible without paging through individual notes.

The chart, done well, reads like a clinician thinking through the case. The complex med-management visit is the visit type where that quality matters most.

Documenting a complex outpatient psychiatric medication management visit